Genetic Analysis AS: Mandatory notification of trade – Primary Insider

Report this content

OSLO, NORWAY - 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management has bought GEAN-shares.

Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today bought 23.000 GEAN-shares at an average price of 3,68 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 192.040 shares and 49,998 tradable subscription rights GEAN T01/T02.

For further information, please contact:
Ronny Hermansen, Chief Executive Officer

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 24 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.